Trial reportProbiotics and antimicrobial proteins2023
Comparing the Effect of Probiotic and Fluconazole on Treatment and Recurrence of Vulvovaginal Candidiasis: a Triple-Blinded Randomized Controlled Trial.
Trial report in Probiotics and antimicrobial proteins, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- OteseconazoleRevista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2026Pooled it
- The role of probiotics in restoring and maintaining vaginal microbiome health: a review.Infection and immunity · 2026Review
- Limosilactobacillus fermentum 21 N1 Mitigates Candida albicans-Induced Vulvovaginal Candidiasis and Suppresses NLRP3 Inflammasome Activation in a Mouse Model.Probiotics and antimicrobial proteins · 2026Article
- Complementary Use of Probiotics and Their Antimicrobial Proteins in Brucellosis: A Comprehensive Review of Mechanisms and Clinical Benefits.Probiotics and antimicrobial proteins · 2026Review
- Gut bacteria: protective mediators, pathogenic contributors and novel therapeutic targets in Candida albicans infections.Gut pathogens · 2025Review
- Statins as Antifungal Agents: A Review on Drug Repurposing and Nanotechnology-Driven Delivery Strategies.Fundamental & clinical pharmacology · 2025Review
- Probiotic Lactobacillus Species Modulate Immune Responses During Vaginal Epithelial Cell Colonization.The Journal of infectious diseases · 2025Article
- Fabrication of a sponge-like protein based hydrogel incorporating fluconazole against Candida species as a potential treatment for vulvovaginal candidiasis infection.Scientific reports · 2025Article
- Vaginal mycobiome characteristics and therapeutic strategies in vulvovaginal candidiasis (VVC): differentiating pathogenic species and microecological features for stratified treatment.Clinical microbiology reviews · 2025Review
- The mechanism research of itraconazole combined with aspirin in the treatment of vulvovaginal candidiasis through NF-κB signaling pathway.Biomolecules & biomedicine · 2025Article
- Leveraging the microbiome to combat antibiotic resistant gynecological infections.npj antimicrobials and resistance · 2025Review
- Improving Vaginal Health with a Zinc-Containing Vaginal Hydrogel.Gels (Basel, Switzerland) · 2025Article
- A PRISMA Systematic Review of Sexual Dysfunction and Probiotics with Pathophysiological Mechanisms.Biology · 2025Review
- Antifungal susceptibility testing and determination of local epidemiological cut-off values forMicrobiology spectrum · 2025Article
- Vaginal Candida albicans infections: host-pathogen-microbiome interactions.FEMS microbiology reviews · 2025Review
- Genetic association between human skin microbiota with vaginitis: a two-sample Mendelian randomization study.Archives of dermatological research · 2025Article
- Effects ofYonsei medical journal · 2024Article
- Probiotics in the Management of Vulvovaginal Candidosis.Journal of clinical medicine · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaginitis is a common problem in women. Candida albicans is responsible for more than 85% of vaginal fungal infections. The aim of this study was to compare the effects of probiotic and fluconazole on the treatment and recurrence of vulvovaginal candidiasis (VVC). This triple-blinded randomized controlled trial was conducted on 80 married women, aged 18-49 years, with VVC, as confirmed by clinical and laboratory diagnosis. The participants were allocated into two groups using blocked randomization method. The fluconazole-treated group received a single dose of fluconazole (150 mg) supplemented with 30 placebo capsules of probiotic, and the probiotic-treated group got 30 probiotic capsules containing 1 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.